查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1434560

抗病毒藥物市場：按藥物類型、治療藥物和最終用途分類 - 2024-2030 年全球預測

Antiviral Drugs Market by Drug Type (Branded Drugs, Generic Drugs), Therapeutics (Acquired Immunodeficiency Syndrome Therapeutics, Hepatitis (B & C) Therapeutics, Herpes Therapeutics), End Use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年抗病毒藥物市場規模為562.2億美元，預計2024年將達到598.4億美元，2030年將達到876.1億美元，複合年成長率為6.54%。

全球抗病毒藥物市場

主要市場統計
基準年[2023] 562.2億美元
預測年份 [2024] 598.4億美元
預測年份 [2030] 876.1億美元
複合年成長率（%） 6.54%
抗病毒藥物市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估抗病毒藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對抗病毒藥物市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-抗病毒藥物市場規模和預測是多少？

2-抗病毒藥物市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3-抗病毒藥物市場的技術趨勢和法律規範是什麼？

4-抗病毒藥物市場主要供應商的市場佔有率是多少？

5-進入抗病毒藥物市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • HIV、肝炎和流感等病毒性疾病增加
      • 政府和私營部門在抗病毒藥物開發方面的支出增加
      • 增加防毒程式和宣傳活動的數量以提高客戶意識
    • 抑制因素
      • 對抗病毒藥物治療成本上升和專利到期的擔憂
    • 機會
      • 針對多種病毒感染疾病和疾病的疫苗生產的研究和開發
      • 用於愛滋病毒疫苗開發的多種配方
    • 任務
      • 同類療法療法等替代療法的普及
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章按藥物類型分類的抗病毒藥物市場

  • 品牌藥品
  • 學名藥

第7章依治療方法分類的抗病毒藥物市場

  • 後天免疫力缺乏症候群的治療方法
  • 肝炎（乙型和丙型）治療藥物
  • 治療皰疹的藥
  • 流感治療藥物
  • 肺炎

第8章抗病毒藥物市場：依最終用途

  • 門診手術中心
  • 診所
  • 醫院

第9章美洲抗病毒藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區抗病毒藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲抗病毒藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析

第13章競爭產品組合

  • 主要公司簡介
    • Abacus Bioscience Inc.
    • Abbott Laboratories
    • AbbVie Inc.
    • Antiva Biosciences, Inc.
    • AstraZeneca PLC
    • Aurobindo Pharma
    • Bristol-Myers Squibb Company
    • Chimerix Inc.
    • Cipla Limited
    • Dr. Reddy's Laboratories Ltd.
    • ENYO Pharma SA
    • F. Hoffmann-La Roche AG
    • Gilead Sciences, Inc.
    • GlaxoSmithKline PLC
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis AG
  • 主要產品系列

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-4358BACA82C1

[180 Pages Report] The Antiviral Drugs Market size was estimated at USD 56.22 billion in 2023 and expected to reach USD 59.84 billion in 2024, at a CAGR 6.54% to reach USD 87.61 billion by 2030.

Global Antiviral Drugs Market

KEY MARKET STATISTICS
Base Year [2023] USD 56.22 billion
Estimated Year [2024] USD 59.84 billion
Forecast Year [2030] USD 87.61 billion
CAGR (%) 6.54%
Antiviral Drugs Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antiviral Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antiviral Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antiviral Drugs Market, highlighting leading vendors and their innovative profiles. These include Abacus Bioscience Inc., Abbott Laboratories, AbbVie Inc., Antiva Biosciences, Inc., AstraZeneca PLC, Aurobindo Pharma, Bristol-Myers Squibb Company, Chimerix Inc., Cipla Limited, Dr. Reddy's Laboratories Ltd., ENYO Pharma SA, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., and Novartis AG.

Market Segmentation & Coverage

This research report categorizes the Antiviral Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Type
    • Branded Drugs
    • Generic Drugs
  • Therapeutics
    • Acquired Immunodeficiency Syndrome Therapeutics
    • Hepatitis (B & C) Therapeutics
    • Herpes Therapeutics
    • Influenza Therapeutics
    • Pneumonia
  • End Use
    • Ambulatory Surgical Centres
    • Clinics
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antiviral Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antiviral Drugs Market?

3. What are the technology trends and regulatory frameworks in the Antiviral Drugs Market?

4. What is the market share of the leading vendors in the Antiviral Drugs Market?

5. Which modes and strategic moves are suitable for entering the Antiviral Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Antiviral Drugs Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing occurrence of viral diseases such as HIV, hepatitis, and influenza
      • 5.1.1.2. Rising government and private sector expenditure in the development of antiviral drugs
      • 5.1.1.3. Growing number of antiviral programs and campaigns to increase customer awareness
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of antiviral drug treatment and concerns of patent expiration
    • 5.1.3. Opportunities
      • 5.1.3.1. Research and development in the production of vaccines for numerous viral infections and diseases
      • 5.1.3.2. Extensive formulations to develop HIV vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Prevalence of alternative therapy such as homeopathy
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Antiviral Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Branded Drugs
  • 6.3. Generic Drugs

7. Antiviral Drugs Market, by Therapeutics

  • 7.1. Introduction
  • 7.2. Acquired Immunodeficiency Syndrome Therapeutics
  • 7.3. Hepatitis (B & C) Therapeutics
  • 7.4. Herpes Therapeutics
  • 7.5. Influenza Therapeutics
  • 7.6. Pneumonia

8. Antiviral Drugs Market, by End Use

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centres
  • 8.3. Clinics
  • 8.4. Hospitals

9. Americas Antiviral Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antiviral Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antiviral Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abacus Bioscience Inc.
    • 13.1.2. Abbott Laboratories
    • 13.1.3. AbbVie Inc.
    • 13.1.4. Antiva Biosciences, Inc.
    • 13.1.5. AstraZeneca PLC
    • 13.1.6. Aurobindo Pharma
    • 13.1.7. Bristol-Myers Squibb Company
    • 13.1.8. Chimerix Inc.
    • 13.1.9. Cipla Limited
    • 13.1.10. Dr. Reddy's Laboratories Ltd.
    • 13.1.11. ENYO Pharma SA
    • 13.1.12. F. Hoffmann-La Roche AG
    • 13.1.13. Gilead Sciences, Inc.
    • 13.1.14. GlaxoSmithKline PLC
    • 13.1.15. Johnson & Johnson
    • 13.1.16. Merck & Co., Inc.
    • 13.1.17. Novartis AG
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ANTIVIRAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIVIRAL DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTIVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIVIRAL DRUGS MARKET DYNAMICS
  • FIGURE 7. ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 8. ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
  • FIGURE 10. ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2023 VS 2030 (%)
  • FIGURE 12. ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ANTIVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ANTIVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTIVIRAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTIVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIVIRAL DRUGS MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTIVIRAL DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 9. ANTIVIRAL DRUGS MARKET SIZE, BY ACQUIRED IMMUNODEFICIENCY SYNDROME THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS (B & C) THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTIVIRAL DRUGS MARKET SIZE, BY HERPES THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTIVIRAL DRUGS MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 15. ANTIVIRAL DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTRES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 145. ANTIVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 146. ANTIVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. ANTIVIRAL DRUGS MARKET LICENSE & PRICING